Defining 'full-length' recombinant factor VIII: a comparative structural analysis.
about
Expression and characterization of a codon-optimized blood coagulation factor VIII.Purification and characterization of a new recombinant factor VIII (N8).Efficacy, Safety, and Pharmacokinetics of Beroctocog Alfa in Patients Previously Treated for Hemophilia A.Functional factor VIII made with von Willebrand factor at high levels in transgenic milkThe use of PEGylated liposomes in the development of drug delivery applications for the treatment of hemophilia.Blood Clotting Factor VIII: From Evolution to Therapy.Turoctocog alfa (NovoEight®)--from design to clinical proof of concept.Turoctocog alfa: an evidence-based review of its potential in the treatment of hemophilia ABAY 81-8973, a full-length recombinant factor VIII: manufacturing processes and product characteristics.In vitro characterization of recombinant factor VIII concentrates reveals significant differences in protein content, activity and thrombin activation profile.Enhanced Proteolytic Processing of Recombinant Human Coagulation Factor VIII B-Domain Variants by Recombinant Furins.Biochemical and functional characterization of a recombinant monomeric factor VIII-Fc fusion proteinBinding of recombinant human coagulation factor VIII to lipid nanotubes.Structural analysis of the recombinant therapeutic product rFVIII and its PEGylated variants using 2-D DIGE.Identification of Aggregates in Therapeutic Formulations of Recombinant Full-Length Factor VIII Products by Sedimentation Velocity Analytical Ultracentrifugation.Mixture of three amino acids as stabilizers replacing albumin in lyophilization of new third generation recombinant factor VIII GreenGene F.
P2860
Q30397756-14086A0F-690E-462D-8783-AE697674CE93Q30881997-00AC413B-0724-415D-AA72-6AF6D2C43CA4Q35778288-E3779D38-4E92-42DE-B137-96E445893543Q36239576-7EEDD4EC-CC9B-4992-BC23-70CE655F95BEQ37790614-AB514B60-EC00-4A6E-A44F-719FEBCCF532Q38118763-4F4FE78C-4B41-4022-B259-145F18BAE25DQ38209486-2E2EC918-C5D6-4C2A-A28C-37A6FF31F61CQ38408739-0FDE007F-9ED8-4573-A3BC-F9362C86C603Q38725317-B8DF2623-667E-4749-A938-C6F1DC52F91CQ39223784-1BCBD34A-9823-4B39-BA2B-F252423160C4Q39811881-A808E696-85FB-4FAD-A128-4D96CE58A2CDQ41611929-15D68AFF-0665-48DE-858B-D6D96124989AQ41622973-BF38616B-CA30-4291-980C-A8BF04C1EDB8Q45869545-FAFAEE39-34D8-4422-BAEA-A2E0E55F37C6Q45875342-3F7450BE-5AA3-49F3-8EEE-29CC7DFADC92Q50490090-F095DAE2-2CC7-4B81-AB37-502DA420E95E
P2860
Defining 'full-length' recombinant factor VIII: a comparative structural analysis.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Defining 'full-length' recombinant factor VIII: a comparative structural analysis.
@ast
Defining 'full-length' recombinant factor VIII: a comparative structural analysis.
@en
type
label
Defining 'full-length' recombinant factor VIII: a comparative structural analysis.
@ast
Defining 'full-length' recombinant factor VIII: a comparative structural analysis.
@en
prefLabel
Defining 'full-length' recombinant factor VIII: a comparative structural analysis.
@ast
Defining 'full-length' recombinant factor VIII: a comparative structural analysis.
@en
P2093
P2860
P1433
P1476
Defining 'full-length' recombinant factor VIII: a comparative structural analysis.
@en
P2093
P2860
P356
10.1111/J.1365-2516.2006.01388.X
P577
2007-01-01T00:00:00Z